Trump's 15% Tariff Sparks UK–EU Confusion and Market Risk

Executive summary

A new U.S. presidential tariff announced at a 15% flat rate has created immediate legal and market uncertainty for the UK, EU and key trading partners. The administration invoked Section 122 of the Trade Act of 1974 to impose a temporary 15% tariff that will last up to 150 days unless extended by Congress. The US Supreme Court earlier struck down tariffs enacted under the IEEPA, covering roughly 70% of additional tariffs imposed in the president’s second term, prompting the administration to adopt a different legal route.

Key data points:

• Announced tariff: 15% flat global surcharge on many imports.
• Duration: up to 150 days under Section 122 unless Congress votes to extend.
• IEEPA-related tariffs previously covered ~70% of additional tariffs and were declared illegal by the Supreme Court.
• Notable trial readouts: Novo Nordisk CagriSema weight-loss trial showed 23.0% weight loss vs 25.5% for a competitor at 84 weeks (market reaction: shares down ~8.5%).

What changed and why it matters

The administration’s shift from IEEPA-based tariffs to Section 122 resets the legal basis for broad import surcharges. Section 122 allows temporary measures in response to a declared balance-of-payments crisis; critics and some economists question whether current U.S. external financing conditions meet that standard in a floating-rate regime.

Immediate implications:

• Trade certainty is reduced for countries that negotiated bilateral or multilateral tariff arrangements with the U.S. (including the UK, EU, Japan, Switzerland and others).
• The U.S. has indicated certain exclusions—critical minerals, pharmaceuticals, USMCA-compliant goods from Canada and Mexico and sectors already covered by Section 232 (e.g., cars, steel, aluminium) are not targeted under the new 15% measure.

Market reaction and indices to watch

• Equity markets in Europe opened lower: DAX and CAC slipped as traders priced increased trade risk; the FTSE 100 opened lower amid trade uncertainty.
• Sector pressure: autos (e.g., BMW), aerospace and industrial suppliers face direct demand risk; financials and exporters also vulnerable to volatility in currency and hedging costs.
• Shorter-term safe-haven flows and commodity moves (e.g., gold hitting a three-week high) reflect risk-off positioning.

Tickers and indices relevant to market monitoring: FTSE, DAX, AEX, CAC, BMW.

Legal uncertainty and timelines

• Supreme Court ruling: IEEPA-based tariffs were struck down, removing the legal foundation for roughly 70% of the additional tariffs previously imposed.
• Administration response: invocation of Section 122 (Trade Act of 1974) to impose a temporary 15% tariff for up to 150 days.
• Likely legal pathway: Section 122 has not been used previously at this scale; any court challenges could take time. Questions remain on what qualifies as a “large and serious” balance-of-payments problem under the statute.

Investors should track: legal challenges, Commerce and Treasury guidance, and any clarifications on how previously collected tariff revenues will be treated.

Trade partners, winners and losers

• Short-term beneficiaries: Asian exporters such as China, India and Vietnam may gain relative competitiveness if U.S. tariff architecture shifts; analysts highlight Vietnam as a possible production-base winner under a flat 15% regime.
• Limited beneficiaries: Japan and South Korea may see marginal tariff changes but retain strategic trade and investment ties with the U.S.
• Sectors at risk: automotive, aerospace, machinery and pharmaceuticals that rely on integrated transatlantic supply chains face immediate demand and logistical disruption.

Supply-chain and corporate impact (UK focus)

• UK exposure: a move from an existing 10% bilateral tariff rate with the U.S. to 15% would push UK exporters into a less competitive position in some sectors and increase cost pressure on transatlantic production lines.
• Operational effects: order cancellations, inventory buildup, rerouted logistics, higher freight and hedging costs, and potential short-term cash-flow stress for smaller suppliers.
• Policy uncertainty: pause in EU parliamentary ratification processes and requests for additional clarity from trading partners amplify planning risk.

Practical guidance for institutional investors and corporate treasuries

1. Scenario planning: model revenue and margin impacts under 10%, 15% and potential targeted tariff escalations (Sections 232/301). Include FX and hedging cost sensitivity.

2. Counterparty review: assess exposure to U.S. demand channels, USMCA rules of origin, and suppliers located in tariff-exempt categories (e.g., USMCA-compliant goods).

3. Liquidity stress-testing: quantify working-capital impacts for smaller suppliers embedded in transatlantic chains.

4. Monitor legal filings and official guidance for refund policy on previously collected IEEPA tariffs and for any formal declarations of balance-of-payments emergency.

What to watch next (short list)

• Official U.S. guidance on implementation timing and exclusions for the 15% tariff.
• Statements and actions from the EU and UK on reciprocal measures or pauses to trade agreements.
• Legal challenge filings that could affect the enforceability or duration of the Section 122 measure.
• Macro indicators: changes in demand, CPI and yields as markets reprice trade risk.

Bottom line

The shift to a 15% global tariff under Section 122 has immediately increased trade policy uncertainty and market volatility. The measure is temporary (up to 150 days) but its economic and legal consequences are material for exporters, multinational supply chains and equity markets across FTSE, DAX and other European indices. Institutional investors should prioritize scenario analysis, liquidity planning and close monitoring of legal developments and official clarifications.

---

Notable datapoints repeated for citation

• 15% announced global tariff rate.
• 150-day maximum duration under Section 122 unless Congress extends.
• Supreme Court struck down IEEPA-based tariffs that accounted for roughly 70% of additional tariffs in the president's second term.
• Novo Nordisk CagriSema 84-week trial: 23.0% weight loss vs 25.5% for comparator; company shares fell ~8.5% on the result.